Skip to main content
SpringerLink
Log in

Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The report of Janus Kinase 2 (JAK2) mutations in myeloid malignancies with high frequency in myeloproliferative neoplasms has been well known since 2005. By monitoring allele burden, it is found that the expression of JAK2V617F mutation is increasing significantly from essential thrombocytosis to polycythemia vera. Furthermore, JAK2 abnormalities are reported in the majority of unexplained thrombotic episodes. Thalassemic syndromes are characterized by ineffective erythropoiesis and thrombocytosis, mainly due to splenectomy. The high incidence of thromboembolic events has led to the identification of a prothrombotic state in these patients. The contribution of JAK2 mutations to the hypercoagulable state of thalassemic patients is still unknown. Furthermore, the potential role of Janus Kinase mutations in hepcidin expression and consequently in ineffective erythropoiesis is still under investigation. This study was scheduled to determine whether the presence of JAK2V617F mutation in thalassemic patients is associated with thrombocytosis. We studied 20 patients DNA with beta-thalassemia for JAK2V617F mutation by using RG-PCR method. None of the patients were positive for this particular mutation. More studies are needed to prove the role of JAK2 in ineffective erythropoiesis, iron metabolism and thrombocytosis and to determine if using JAK2 inhibitors in thalassemic patients can be a potential therapeutic option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G (2005) Coagulation and splenectomy: an overview. Ann N Y Acad Sci 1054:317–324

    Article  PubMed  CAS  Google Scholar 

  2. Rivella S (2009) Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 16(3):187–194

    Article  PubMed  CAS  Google Scholar 

  3. Mohammed KA (2009) The role of Jak2 abnormalities in hematologic neoplasms. Hematol Rev 1e10:56–61

    Google Scholar 

  4. Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, Hoffbrand AV, Patch D, McNamara C (2008) The JAK2 (V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 30(5):415–419

    Article  PubMed  CAS  Google Scholar 

  5. Taher A, Shammaa D, Bazarbachi A, Itani D, Zaatari G, Greige L, Otrock ZK, Mahfouz RA (2009) Absence of JAK2V617F mutation in thalassemia intermedia patients. Mol Biol Rep 36(6):1555–1557

    Article  PubMed  CAS  Google Scholar 

  6. Krichevsky S, Borohovitz A, Prus J, Perlman R, Weinberg I, Abramovitz J, Treves A, Fibach E, Ben-Yehuda D The JAK2V617F mutation in non-MPD individuals occurs at a low frequency during erythroid differentiation and not in the stem cells. Blood Poster Board I-563. 52nd ASH

  7. Steensma DP (2006) JAK2V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 8(4):397–411

    Article  PubMed  CAS  Google Scholar 

  8. Hirsh J, Dacie JV (1966) Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol 12(1):44–53

    Article  PubMed  CAS  Google Scholar 

  9. Ikeda M, Sekimoto M, Takiguchi S, Kubota M, Ikenaga M, Yamamoto H, Fujiwara Y, Ohue M, Yasuda T, Imamura H, Tatsuta M, Yano M, Furukawa H, Monden M (2005) High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg 241(2):208–216

    Article  PubMed  Google Scholar 

  10. Mohren M, Markmann I, Dworschak U, Franke A, Maas C, Mewes S, Weiss G, Jentsch-Ullrich K (2004) Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol 76(2):143–147

    Article  PubMed  Google Scholar 

  11. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, Bhamarapravati N (1997) Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health 28(Suppl. 3):141A–148A

    Google Scholar 

  12. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350(9):886–895

    Article  PubMed  CAS  Google Scholar 

  13. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A (1993) Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 44(1):63–65

    Article  PubMed  CAS  Google Scholar 

  14. Cappellini MD, Tavazzi D, Duca L, Graziadei G, Mannu F, Turrini F, Arese P, Fiorelli G (1999) Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band three aggregation and erythrophagocytosis in beta-thalassaemia intermedia. Br J Haematol 104(3):504–512

    Article  PubMed  CAS  Google Scholar 

  15. Pritchard MA, Baker E, Callen DF, Sutherland GR, Wilks AF (1992) Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24. Mamm Genome 3(1):36–38

    Article  PubMed  CAS  Google Scholar 

  16. Saltzman A, Stone M, Franks C, Searfoss G, Munro R, Jaye M, Ivashchenko Y (1998) Cloning and characterization of human JAK-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem Biophys Res Commun 246(3):627–633

    Article  PubMed  CAS  Google Scholar 

  17. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74(2):227–236

    Article  PubMed  CAS  Google Scholar 

  18. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 23(10):1708–1715

    Article  PubMed  CAS  Google Scholar 

  19. McLornan D, Percy M, McMullin MF (2006) JAK2V617F: a single mutation in the myeloproliferative group of disorders. Ulster Med J 75(2):112–119

    PubMed  Google Scholar 

  20. Hellström-Lindberg E, Cazzola M (2008) The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 52–59

  21. Libani IV, Guy EC, Melchiori L, Schiro R, Ramos P, Breda L, Scholzen T, Chadburn A, Liu Y, Kernbach M, Baron-Lühr B, Porotto M, de Sousa M, Rachmilewitz EA, Hood JD, Cappellini MD, Giardina PJ, Grady RW, Gerdes J, Rivella S (2008) Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 112(3):875–885

    Article  PubMed  CAS  Google Scholar 

  22. Melchiori L, Gardenghi S, Rivella S (2010) beta-Thalassemia: hijaking ineffective erythropoiesis and iron overload. Adv Hematol 2010:938640

    PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Thalassemia Unit, Hippokration Hospital, Thessaloniki, Greece

    E. Vlachaki, V. Perifanis & F. Klonizakis

  2. 2nd Department of Internal Medicine, Aristotelion University, Hippokration Hospital, Thessaloniki, Greece

    A. Kalogeridis, E. Ioannidou & I. Klonizakis

  3. Hematological Clinic, General Hospital, Limassol, Cyprus

    N. Neokleous

Authors
  1. E. Vlachaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Kalogeridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Neokleous
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Perifanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Klonizakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Ioannidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Klonizakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Neokleous.

Additional information

All the authors contributed equally to conception, design and drafting the article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlachaki, E., Kalogeridis, A., Neokleous, N. et al. Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy. Mol Biol Rep 39, 6101–6105 (2012). https://doi.org/10.1007/s11033-011-1425-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-011-1425-7

Keywords

Search

Navigation